Annual Retained Earnings
-$365.89 M
-$135.35 M-58.71%
31 December 2023
Summary:
Monte Rosa Therapeutics annual retained earnings is currently -$365.89 million, with the most recent change of -$135.35 million (-58.71%) on 31 December 2023. During the last 3 years, it has fallen by -$317.81 million (-661.05%). GLUE annual retained earnings is now -2899.57% below its all-time high of -$12.20 million, reached on 31 December 2019.GLUE Retained Earnings Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Retained Earnings
-$452.02 M
-$23.86 M-5.57%
30 September 2024
Summary:
Monte Rosa Therapeutics quarterly retained earnings is currently -$452.02 million, with the most recent change of -$23.86 million (-5.57%) on 30 September 2024. Over the past year, it has dropped by -$119.39 million (-35.89%). GLUE quarterly retained earnings is now -840.21% below its all-time high of -$48.08 million, reached on 31 December 2020.GLUE Quarterly Retained Earnings Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
GLUE Retained Earnings Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -58.7% | -35.9% |
| 3 y3 years | -661.0% | -358.5% |
| 5 y5 years | - | - |
GLUE Retained Earnings High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -661.0% | at low | -358.5% | at low |
| 5 y | 5 years | -2899.6% | at low | -840.2% | at low |
| alltime | all time | -2899.6% | at low | -840.2% | at low |
Monte Rosa Therapeutics Retained Earnings History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | -$452.02 M(+5.6%) |
| June 2024 | - | -$428.17 M(+7.6%) |
| Mar 2024 | - | -$397.86 M(+8.7%) |
| Dec 2023 | -$365.89 M(+58.7%) | -$365.89 M(+10.0%) |
| Sept 2023 | - | -$332.64 M(+11.7%) |
| June 2023 | - | -$297.75 M(+13.4%) |
| Mar 2023 | - | -$262.57 M(+13.9%) |
| Dec 2022 | -$230.54 M | -$230.54 M(+15.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2022 | - | -$199.75 M(+15.8%) |
| June 2022 | - | -$172.44 M(+18.1%) |
| Mar 2022 | - | -$145.97 M(+19.6%) |
| Dec 2021 | -$122.03 M(+153.8%) | -$122.03 M(+23.8%) |
| Sept 2021 | - | -$98.59 M(+25.2%) |
| June 2021 | - | -$78.76 M(+30.5%) |
| Mar 2021 | - | -$60.35 M(+25.5%) |
| Dec 2020 | -$48.08 M(+294.1%) | -$48.08 M |
| Dec 2019 | -$12.20 M | - |
FAQ
- What is Monte Rosa Therapeutics annual retained earnings?
- What is the all time high annual retained earnings for Monte Rosa Therapeutics?
- What is Monte Rosa Therapeutics annual retained earnings year-on-year change?
- What is Monte Rosa Therapeutics quarterly retained earnings?
- What is the all time high quarterly retained earnings for Monte Rosa Therapeutics?
- What is Monte Rosa Therapeutics quarterly retained earnings year-on-year change?
What is Monte Rosa Therapeutics annual retained earnings?
The current annual retained earnings of GLUE is -$365.89 M
What is the all time high annual retained earnings for Monte Rosa Therapeutics?
Monte Rosa Therapeutics all-time high annual retained earnings is -$12.20 M
What is Monte Rosa Therapeutics annual retained earnings year-on-year change?
Over the past year, GLUE annual retained earnings has changed by -$135.35 M (-58.71%)
What is Monte Rosa Therapeutics quarterly retained earnings?
The current quarterly retained earnings of GLUE is -$452.02 M
What is the all time high quarterly retained earnings for Monte Rosa Therapeutics?
Monte Rosa Therapeutics all-time high quarterly retained earnings is -$48.08 M
What is Monte Rosa Therapeutics quarterly retained earnings year-on-year change?
Over the past year, GLUE quarterly retained earnings has changed by -$119.39 M (-35.89%)